S3-guideline "Exocrine pancreatic carcinoma" 2007: Results of an evidence-based consensus conference (13.-14.10.2006)

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 5, 2008, Pages 449-482

  Adler, Guido ^a   Seufferlein, T ^a   Bischoff, S C ^a   Brambs, H J ^a   Feuerbach, S ^a   Grabenbauer, C ^a   Hahn, S ^a   Heinemann, V ^a   Hohenberger, W ^a   Langrehr, J M ^a   Lutz, M P ^a   Micke, O ^a   Neuhaus, H ^a   Neuhaus, P ^a   Oettle, H ^a   Schlag, P M ^a   Schmid, R ^a   Schmiegel, W ^a   Schlottmann, K ^a   Wemer, J ^a   Wiedenmann, B ^a   Kopp, I ^a   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIRHEUMATIC AGENT; ASCORBIC ACID; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; OXALIPLATIN; SOMATOSTATIN;

ADD ON THERAPY; ADJUVANT THERAPY; ALCOHOL CONSUMPTION; CANCER GRADING; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CYSTIC FIBROSIS; DIAGNOSTIC IMAGING; DIET THERAPY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EVIDENCE BASED MEDICINE; FOOD INTAKE; GASTROENTEROSTOMY; HUMAN; INCIDENCE; INOPERABLE CANCER; LIFESTYLE MODIFICATION; MONOTHERAPY; OCCUPATIONAL EXPOSURE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PANCREAS DUCT STENOSIS; PANCREAS FISTULA; PANCREAS RESECTION; PANCREAS SURGERY; PRACTICE GUIDELINE; RADIOFREQUENCY ABLATION; RISK REDUCTION; SKIN MANIFESTATION; STENT; UNSPECIFIED SIDE EFFECT;

EID: 47649131231     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027420     Document Type: Conference Paper

References (299)

1. Adler G, Seufferlein T, Bischoff SC et al. S3-Guidelines "Exocrine pancreatic cancer" 2007. Z Gastroenterol 2007; 45: 487-523
2. Glade MJ. Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutrition 1999; 15: 523-526
3. Fernandez E, La Vecchia C, Decani A. Attributable risks for pancreatic cancer in northern Italy. Cancer Epidemiol Biomarkers Prev 1996; 5: 23-27
4. Ji BT, Chow WH, Gridley G et al. Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai China. Cancer Epidemiol Biomarkers Prev 1995; 4: 885-893
5. Soler M, Chatenoud L, La Vecchia C et al. Diet, alcohol, coffee and pancreatic cancer: final results from an Italian study. Eur J Cancer Prev 1998; 7: 455-460
6. Nkondjock A, Krewski D, Johnson KC et al. Dietary patterns and risk of pancreatic cancer. Int J Cancer 2005; 114: 817-823
7. Nothlings U, Wilkens LR, Murphy SP et al. Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study. J Natl Cancer Inst 2005; 97: 1458-1465
8. Michaud DS, Giovannucci E, Willett WC et al. Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol 2003; 157: 1115-1125
9. Michaud DS, Skinner HG, Wu K et al. Dietary patterns and pancreatic cancer risk in men and women. J Natl Cancer Inst 2005; 97: 518-524
10. Hine RJ, Srivastava S, Milner JA et al. Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report. Pancreas 2003; 27: 356-366
11. de Bueno Mesquita HB, Maisonneuve P, Runia S et al. Intake of foods and nutrients and cancer of the exocrine pancreas: a population-based case-control study in The Netherlands. Int J Cancer 1991; 48: 540-549
12. Lyon JL, Slattery ML, Mahoney AW et al. Dietary intake as a risk factor for cancer of the exocrine pancreas. Cancer Epidemiol Biomarkers Prev 1993; 2: 513-518
13. Fraser GE. Associations between diet and cancer, ischemic heart disease, and all-cause mortality in non-Hispanic white California Seventh-day Adventists. Am J Clin Nutr 1999; 70: 532S-538S
14. Mills PK, Beeson WL, Abbey DE et al. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988; 61: 2578-2585
15. Chan JM, Wang F, Holly EA. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. Cancer Epidemiol Biomarkers Prev 2005; 14: 2093-2097
16. Negri E, La Vecchia C, Franceschi S et al. Vegetable and fruit consumption and cancer risk. Int J Cancer 1991; 48: 350-354
17. Larsson SC, Hakansson N, Naslund I et al. Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 301-305
18. Vainio H, Weiderpass E. Fruit and vegetables in cancer prevention. Nutr Cancer 2006; 54: 111-142
19. Lin Y, Tamakoshi A, Hayakawa T et al. Nutritional factors and risk of pancreatic cancer: a population-based case-control study based on direct interview in Japan. J Gastroenterol 2005; 40: 297-301
20. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR et al. Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol 2002; 155: 783-792
21. Zhang J, Zhao Z, Berkel HJ. Animal fat consumption and pancreatic cancer incidence: evidence of interaction with cigarette smoking. Ann Epidemiol 2005; 15: 500-508
22. Anderson KE, Sinha R, Kulldorff M et al. Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res 2002; 506-507: 225-231
23. Anderson KE, Kadlubar FF, Kulldorff M et al. Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2261-2265
24. Ghadirian P, Baillargeon J, Simard A et al. Food habits and pancreatic cancer: a case-control study of the Francophone community in Montreal, Canada. Cancer Epidemiol Biomarkers Prev 1995; 4: 895-899
25. Fernandez E, Chatenoud L, La Vecchia C et al. Fish consumption and cancer risk. Am J Clin Nutr 1999; 70: 85-90
26. Michaud DS, Liu S, Giovannucci E et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002; 94: 1293-1300
27. Silvera SA, Rohan TE, Jain M et al. Glycemic index, glycemic load, and pancreatic cancer risk (Canada). Cancer Causes Control 2005; 16: 431-436
28. Schernhammer ES, Hu FB, Giovannucci E et al. Sugar-sweetened soft drink consumption and risk of pancreatic cancer in two prospective cohorts. Cancer Epidemiol Biomarkers Prev 2005; 14: 2098-2105
29. Lin Y, Tamakoshi A, Kawamura T et al. Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk. Int J Cancer 2002; 99: 742-746
30. Michaud DS, Giovannucci E, Willett WC et al. Coffee and alcohol consumption and the risk of pancreatic cancer in two prospective United States cohorts. Cancer Epidemiol Biomarkers Prev 2001; 10: 429-437
31. Silverman DT. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratog Carcinog Mutagen 2001; 21: 7-25
32. Brown LM. Epidemiology of alcohol-associated cancers. Alcohol 2005; 35: 161-168
33. Ye W, Lagergren J, Weiderpass E et al. Alcohol abuse and the risk of pancreatic cancer. Gut 2002; 51: 236-239
34. Talamini G, Bassi C, Falconi M et al. Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Dig Dis Sci 1999; 44: 1303-1311
35. MacMahon B, Yen S, Trichopoulos D et al. Coffee and cancer of the pancreas. N Engl J Med 1981; 304: 630-633
36. Gullo L, Pezzilli R, Morselli-Labate AM. Coffee and cancer of the pancreas: an Italian multicenter study. The Italian Pancreatic Cancer Study Group. Pancreas 1995; 11: 223-229
37. Lyon JL, Mahoney AW, French TK et al. Coffee consumption and the risk of cancer of the exocrine pancreas: a case-control study in a low-risk population. Epidemiology 1992; 3: 164-170
38. Harnack LJ, Anderson KE, Zheng W et al. Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 1997; 6: 1081-1086
39. Qiu D, Kurosawa M, Lin Y et al. Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. J Epidemiol 2005; 15 (Suppl 2): S157-167
40. Tavani A, La Vecchia C. Coffee and cancer: a review of epidemiological studies, 1990-1999. Eur J Cancer Prev 2000; 9: 241-256
41. La Vecchia C, Negri E, Franceschi S et al. Tea consumption and cancer risk. Nutr Cancer 1992; 17: 27-31
42. Nagano J, Kono S, Preston DL et al. A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). Cancer Causes Control 2001; 12: 501-508
43. Hemminki K, Dong C, Vaittinen P. Cancer risks to spouses and offspring in the Family-Cancer Database. Genet Epidemiol 2001; 20: 247-257
44. Hemminki K, Jiang Y. Cancer risks among long-standing spouses. Br J Cancer 2002; 86: 1737-1740
45. Nilsen TI, Vatten LJ. A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trondelag, Norway. Cancer Causes Control 2000; 11: 645-652
46. Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003; 89: 519-523
47. Michaud DS, Giovannucci E, Willett WC et al. Physical activity, obesity, height, and the risk of pancreatic cancer. Jama 2001; 286: 921-929
48. Patel AV, Rodriguez C, Bernstein L et al. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U. S. Cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 459-466
49. Rapp K, Schroeder J, Klenk J et al. Obesity and incidence of cancer: a large cohort study of over 145000 adults in Austria. Br J Cancer 2005; 93: 1062-1067
50. Larsson SC, Permert J, Hakansson N et al. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer 2005; 93: 1310-1315
51. Berrington de Gonzalez A, Spencer EA, Bueno-de-Mesquita HB et al. Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2006; 15: 879-885
52. Silverman DT, Swanson CA, Gridley G et al. Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1998; 90: 1710-1719
53. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR et al. A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 2002; 13: 417-426
54. Hanley AJ, Johnson KC, Villeneuve PJ et al. Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. Int J Cancer 2001; 94: 140-147
55. Coughlin SS, Calle EE, Patel AV et al. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000; 11: 915-923
56. Lin Y, Tamakoshi A, Kawamura T et al. A prospective cohort study of cigarette smoking and pancreatic cancer in Japan. Cancer Causes Control 2002; 13: 249-254
57. Yun YH, Jung KW, Bae JM et al. Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study. Cancer Detect Prev 2005; 29: 15-24
58. Chiu BC, Lynch CF, Cerhan JR et al. Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in Iowa. Ann Epidemiol 2001; 11: 28-37
59. Bonelli L, Aste H, Bovo P et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 2003; 27: 143-149
60. Duell EJ, Holly EA, Bracci PM et al. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 2002; 94: 297-306
61. Miyasaka K, Kawanami T, Shimokata H et al. Inactive aldehyde dehydrogenase-2 increased the risk of pancreatic cancer among smokers in a Japanese male population. Pancreas 2005; 30: 95-98
62. Wang L, Miao X, Tan W et al. Genetic polymorphisms in methylene-tetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol 2005; 3: 743-751
63. Villeneuve PJ, Johnson KC, Mao Y et al. Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian population-based case-control study. Can J Public Health 2004; 95: 32-37
64. Alguacil J, Pollan M, Gustavsson P. Occupations with increased risk of pancreatic cancer in the Swedish population. Occup Environ Med 2003; 60: 570-576
65. Alguacil J, Porta M, Benavides FG et al. Occupation and pancreatic cancer in Spain: a case-control study based on job titles. PANKRAS II Study Group. Int J Epidemiol 2000; 29: 1004-1013
66. Laakkonen A, Kauppinen T, Pukkala E. Cancer risk among Finnish food industry workers. Int J Cancer 2006; 118: 2567-2571
67. Fryzek JP, Garabrant DH, Harlow SD et al. A case-control study of self-reported exposures to pesticides and pancreas cancer in southeastern Michigan. Int J Cancer 1997; 72: 62-67
68. Ji BT, Silverman DT, Stewart PA et al. Occupational exposure to pesticides and pancreatic cancer. Am J Ind Med 2001; 39: 92-99
69. Ojajarvi IA, Partanen TJ, Ahlbom A et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 2000; 57: 316-324
70. Ojajarvi A, Partanen T, Ahlbom A et al. Risk of pancreatic cancer in workers exposed to chlorinated hydrocarbon solvents and related compounds: a meta-analysis. Am J Epidemiol 2001; 153: 841-850
71. Weiderpass E, Vainio H, Kauppinen T et al. Occupational exposures and gastrointestinal cancers among Finnish women. J Occup Environ Med 2003; 45: 305-315
72. Vassi A, Tate RB, Routledge M. Cancer incidence and mortality in workers employed at a transformer manufacturing plant: update to a cohort study. Am J Ind Med 2003; 44: 58-62
73. Ji J, Hemminki K. Socioeconomic and occupational risk factors for pancreatic cancer: a cohort study in Sweden. J Occup Environ Med 2006; 48: 283-288
74. Bjelakovic G, Nikolova D, Simonetti RG et al. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004; 364: 1219-1228
75. Bjelakovic G, Nikolova D, Simonetti RG et al. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev CD 004 183 2004
76. Harris RE, Beebe-Donk J, Doss H et al. Aspirin, Ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13: 559-583
77. Jacobs EJ, Connell CJ, Rodriguez C et al. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 2004; 96: 524-528
78. Coogan PF, Rosenberg L, Palmer JR et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000; 9: 119-123
79. Homma T, Tsuchiya R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int J Pancreatol 1991; 9: 119-124
80. Kim JE, Lee KT, Lee JK et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19: 182-186
81. McWilliams RR, Rabe KG, Olswold C et al. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005; 104: 388-394
82. Klein AP, Brune KA, Petersen GM et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64: 2634-2638
83. Bartsch DK, Sina-Frey M, Lang S et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 2002; 236: 730-737
84. McFaul CD, Greenhalf W, Earl J et al. Anticipation in familial pancreatic cancer. Gut 2006; 55: 252-258
85. Tersmette AC, Petersen GM, Offerhaus GJ et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7: 738-744
86. Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 2005; 6: 437-445
87. Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621
88. Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-781; quiz 665
89. Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453
90. Lim W, Olschwang S, Keller JJ et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004; 126: 1788-1794
91. Lynch HT, Brand RE, Hogg D et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002; 94: 84-96
92. Rulyak SJ, Brentnall TA, Lynch HT et al. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 2003; 98: 798-804
93. Vasen HF, Gruis NA, Frants RR et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87: 809-811
94. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005; 7: 60
95. Asperen CJvan, Brohet RM, Meijers-Heijboer EJ et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-719
96. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-1365
97. Lilley M, Gilchrist D. The hereditary spectrum of pancreatic cancer: the Edmonton experience. Can J Gastroenterol 2004; 18: 17-21
98. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repairgenes. Int J Cancer 1999; 81: 214-218
99. Geoffroy-Perez B, Janin N, Ossian K et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 2001; 93: 288-293
100. Giardiello FM, Offerhaus GJ, Lee DH et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34: 1394-1396
101. Couch FJ, Johnson MR, Rabe K et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005; 65: 383-386
102. Howes N, Lerch MM, Greenhalf W et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2: 252-261
103. Lowenfels AB, Maisonneuve P, DiMagno EP et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89: 442-446
104. Kimmey MB, Bronner MP, Byrd DR et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56: S82-86
105. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995; 109: 247-251
106. Karlson BM, Ekbom A, Josefsson S et al. The risk of pancreatic cancer following pancreatitis: an association due to confounding? Gastroenterology 1997; 113: 587-592
107. Lowenfels AB, Maisonneuve P, Cavallini G et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437
108. Malka D, Hammel P, Maire F et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002; 51: 849-852
109. Talamini G, Falconi M, Bassi C et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999; 94: 1253-1260
110. Chari ST, Leibson CL, Rabe KG et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129: 504-511
111. Coughlin SS, Calle EE, Teras LR et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-1167
112. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A et al. Type-II diabetes and pancreatic cancer. A meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083
113. Stolzenberg-Solomon RZ, Graubard BI, Chari S et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. Jama 2005; 294: 2872-2878
114. Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-1365
115. Calle EE, Murphy TK, Rodriguez C et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998; 9: 403-410
116. Chow WH, Gridley G, Nyren O et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995; 87: 930-931
117. Silverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830-1837
118. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. Jama 1995; 273: 1605-1609
119. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. N Engl J Med 1994; 331: 81-84
120. Rousseau MC, Parent ME, Pollak MN et al. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006; 118: 2105-2109
121. Bjornsson E, Ismael S, Nejdet S et al. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38: 86-94
122. Reisman Y, Gips CH, Lavelle SM et al. Clinical presentation of (subclinical) jaundice - the Euricterus project in The Netherlands. United Dutch Hospitals and Euricterus Project Management Group. Hepatogastroenterology 1996; 43: 1190-1195
123. Watanabe I, Sasaki S, Konishi M et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 2004; 28: 160-165
124. Balthazar EJ. Pancreatitis associated with pancreatic carcinoma. Pre-operative diagnosis: role of CT imaging in detection and evaluation. Pancreatology 2005; 5: 330-344
125. Mujica VR, Barkin JS, Go VL. Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants. Pancreas 2000; 21: 329-332
126. Adamek HE, Albert J, Breer H et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000; 356: 190-193
127. Hanninen EL, Ricke J, Amthauer H et al. Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2- and T1-weighted sequences for the assessment of suspected pancreatic cancer. Acta Radiol 2005; 46: 117-125
128. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas 1994; 9: 731-734
129. Nazli O, Bozdag AD, Tansug T et al. The diagnostic importance of CEA and CA19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 2000; 47: 1750-1752
130. Ritts Jr RE, Nagorney DM, Jacobsen DJ et al. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994; 9: 707-716
131. Tessler DA, Catanzaro A, Velanovich V et al. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg 2006; 191: 191-197
132. Agarwal B, Abu-Hamda E, Molke KL et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004; 99: 844-850
133. Klapman JB, Chang KJ, Lee JG et al. Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer. Am J Gastroenterol 2005; 100: 2658-2661
134. Varadarajulu S, Wallace MB. Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control 2004; 11: 15-22
135. David O, Green L, Reddy V et al. Pancreatic masses: a multi-institutional study of 364 fine-needle aspiration biopsies with histopathologic correlation. Diagn Cytopathol 1998; 19: 423-427
136. Bipat S, Phoa SS, Delden OM et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005; 29: 438-445
137. Dewitt J, Devereaux BM, Lehman GA et al. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin Gastroenterol Hepatol 2006; 4: 717-725; quiz 664
138. Romagnuolo J, Bardou M, Rahme E et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139: 547-557
139. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 2006; 36: 248-256
140. Schachter PP, Avni Y, Shimonov M et al. The impact of laparoscopy and laparoscopic ultrasonography on the management of pancreatic cancer. Arch Surg 2000; 135: 1303-1307
141. Vollmer CM, Drebin JA, Middleton WD et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg 2002; 235: 1-7
142. van der Waaij LA, Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions. A pooled analysis. Gastrointest Endosc 2005; 62: 383-389
143. Fong Y, Blumgart LH, Fortner JG et al. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 1995; 222: 426-434; discussion 434-437
144. Lightner AM, Glasgow RE, Jordan TH et al. Pancreatic resection in the elderly. J Am Coll Surg 2004; 198: 697-706
145. Lillemoe KD, Cameron JL, Hardacre JM et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999; 230: 322-328; discussion 328-330
146. American College of Physicians. Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery. Ann Intern Med 1997; 127: 309-312
147. Wagner M, Redaelli C, Lietz M et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586-594
148. Fuhrman GM, Leach SD, Staley CA et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996; 223: 154-162
149. Leach SD, Lee JE, Charnsangavej C et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85: 611-617
150. Sasson AR, Hoffman JP, Ross EA et al. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 2002; 6: 147-157; discussion 157-158
151. Nakao A, Takeda S, Inoue S et al. Indications and techniques of extended resection for pancreatic cancer. World J Surg 2006; 30: 976-982; discussion 983-984
152. Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046
153. Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006; 93: 662-673
154. Carrere N, Sauvanet A, Goere D et al. Pancreaticoduodenectomy with mesentericoportal vein resection for adenocarcinoma of the pancreatic head. World J Surg 2006; 30: 1526-1535
155. Riediger H, Makowiec F, Fischer E et al. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006; 10: 1106-1115
156. Bachellier P, Nakano H, Oussoultzoglou PD et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg 2001; 182: 120-129
157. Li B, Chen FZ, Ge XH et al. Pancreatoduodenectomy with vascular reconstruction in treating carcinoma of the pancreatic head. Hepatobiliary Pancreat Dis Int 2004; 3: 612-615
158. Settmacher U, Langrehr JM, Husmann I et al. Reconstruction of visceral arteries with homografts in excision of the pancreas. Chirurg 2004; 75: 1199-1206
159. Schwarz RE. Technical considerations to maintain a low frequency of postoperative biliary stent-associated infections. J Hepatobiliary Pancreat Surg 2002; 9: 93-97
160. Gerke H, White R, Byrne MF et al. Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. Dig Liver Dis 2004; 36: 412-418
161. Jagannath P, Dhir V, Shrikhande S et al. Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy. Br J Surg 2005; 92: 356-361
162. Martignoni ME, Wagner M, Krahenbuhl L et al. Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy. Am J Surg 2001; 181: 52-59; discussion 87
163. Sohn TA, Yeo CJ, Cameron JL et al. Do preoperative biliary stents increase postpancreaticoduodenectomy complications? J Gastrointest Surg 2000; 4: 258-267; discussion 267-268
164. Targarona EM, Garau J, Munoz-Ramos C et al. Single-dose antibiotic prophylaxis in patients at high risk for infection in biliary surgery: a prospective and randomized study comparing cefonicid with mezlocillin. Surgery 1990; 107: 327-334
165. Kujath P, Bouchard R, Scheele J et al. Current perioperative antibiotic prophylaxis. Chirurg 2006; 77: 490, 492-498
166. Connor S, Alexakis N, Garden OJ et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005; 92: 1059-1067
167. Bassi C, Dervenis C, Butturini G et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138: 8-13
168. Finlayson C, Hoffman J, Yeung R et al. Intraoperative ultrasound does not improve detection of liver metastases in resectable pancreatic cancer. Am J Surg 1998; 175: 99-101
169. Kolecki R, Schirmer B. Intraoperative and laparoscopic ultrasound. Surg Clin North Am 1998; 78: 251-271
170. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-465
171. Konishi M, Kinoshita T, Nakagohri T et al. Prognostic value of cytologic examination of peritoneal washings in pancreatic cancer. Arch Surg 2002; 137: 475-480
172. Yachida S, Fukushima N, Sakamoto M et al. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg 2002; 89: 573-578
173. Diener MK, Knaebel HP, Heukaufer C et al. A Systematic Review and Meta-analysis of Pylorus-preserving Versus Classical Pancreaticoduodenectomy for Surgical Treatment of Periampullary and Pancreatic Carcinoma. Ann Surg 2007; 245: 187-200
174. Christein JD, Kendrick ML, Iqbal CW et al. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005; 9: 922-927
175. Shimada K, Sakamoto Y, Sano T et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 2006; 139: 288-295
176. Shoup M, Conlon KC, Klimstra D et al. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg 2003; 7: 946-952; discussion 952
177. Pedrazzoli S, DiCarlo V, Dionigi R et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228: 508-517
178. Farnell MB, Pearson RK, Sarr MG et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138: 618-628; discussion 628-630
179. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236: 355-366; discussion 366-368
180. Brugge WR, Lauwers GY, Sahani D et al. Cystic neoplasms of the pancreas. N Engl J Med 2004; 351: 1218-1226
181. Brugge WR, Lewandrowski K, Lee-Lewandrowski E et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004; 126: 1330-1336
182. Sedlack R, Affi A, Vazquez-Sequeiros E et al. Utility of EUS in the evaluation of cystic pancreatic lesions. Gastrointest Endosc 2002; 56: 543-547
183. Salvia R, Fernandez-del Castillo C, Bassi C et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004; 239: 678-685; discussion 685-687
184. Bassi C, Salvia R, Molinari E et al. Management of 100 consecutive cases of pancreatic serous cystadenoma: wait for symptoms and see at imaging or vice versa? World J Surg 2003; 27: 319-323
185. Hirano S, Kondo S, Ambo Y et al. Outcome of duodenum-preserving resection of the head of the pancreas for intraductal papillary-mucinous neoplasm. Dig Surg 2004; 21: 242-245
186. Takada T, Yasuda H, Amano H et al. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology 1997; 44: 567-573
187. Mann O, Strate T, Schneider C et al. Surgery for advanced and metastatic pancreatic cancer - current state and perspectives. Anticancer Res 2006; 26: 681-686
188. Shrikhande SV, Kleeff J, Reiser C et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 2007; 14: 118-127
189. Friess H, Kleeff J, Silva JC et al. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg 1998; 186: 675-682
190. Urbach DR, Swanstrom LL, Hansen PD. The effect of laparoscopy on survival in pancreatic cancer. Arch Surg 2002; 137: 191-199
191. Santoro E, Carlini M, Carboni F. Laparoscopic pancreatic surgery: indications, techniques and preliminary results. Hepatogastroenterology 1999; 46: 1174-1180
192. Cioc AM, Ellison EC, Proca DM et al. Frozen section diagnosis of pancreatic lesions. Arch Pathol Lab Med 2002; 126: 1169-1173
193. Luttges J, Zamboni G, Kloppel G. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas. A proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist. Dig Surg 1999; 16: 291-296
194. Compton CC, Henson DE. Protocol for the examination of specimens removed from patients with carcinoma of the exocrine pancreas: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med 1997; 121: 1129-1136
195. Sakata E, Shirai Y, Yokoyama N et al. Clinical significance of lymph node micrometastasis in ampullary carcinoma. World J Surg 2006; 30: 985-991
196. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007; 297: 267-277
197. Stocken DD, Buchler MW, Dervenis C et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381
198. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210
199. Penberthy DR, Rich TA, Shelton CH et al. A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer. Ann Oncol 2001; 12: 681-684
200. Mallinson CN, Rake MO, Cocking JB et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281: 1589-1591
201. Palmer KR, Kerr M, Knowles G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-885
202. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600
203. Yip D, Karapetis C, Strickland A et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 3 CD 002 093 2006
204. Burri HA3 rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
205. Storniolo AM, Enas NH, Brown CA et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 85: 1261-1268
206. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516
207. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952
208. Herrmann R, Bodoky G, Rushstaller T et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2005; 23: A4010
209. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E 2297. J Clin Oncol 2002; 20: 3270-3275
210. Van Cutsem E, Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifamib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438
211. Tempero M, Plunkett W, Van Ruiz Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-3408
212. Poplin E, Levy D, Berlin J et al. Phase III trial of gemcitabine (30 min infusion) versus gemcitabine (fixed-dose rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006; 24: LBA4004
213. Maisey N, Chau I, Cunningham D et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002; 20: 3130-3136
214. Ducreux M, Rougier P, Pignon JP et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002; 13: 1185-1191
215. Lutz MP, Koniger M, Muche R et al. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer. Z Gastroenterol 1999; 37: 993-997
216. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94: 902-910
217. Ducreux M, Mitry E, Ould-Kaci M et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 2004; 15: 467-473
218. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine (GEM) vs. gemcitabine plus capecitabine (Gem-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005; 3: PS11
219. Di Costanzo F, Carlini P, Doni L et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005; 93: 185-189
220. Riess M, Helm A, Niedergethmann I et al. A randomised prospective, multicentre phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: A1092
221. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 15: 1960-6
222. Kindler HL, Friberg G, Singh DA et al. Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol 2005; 23: 8033-8040
223. Kindler H, Niedzwiecki D, Hollis D et al. A double-blind, placebo controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Proceedings of the ASCO Gastrointestinal Cancers Symposium 2007; A108
224. Reni M, Passoni P, Bonetto E et al. Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-FIuorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology 2005; 68: 239-245
225. Lutz MP, Van Cutsem E, Wagener T et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 2005; 23: 9250-9256
226. Shepard RC, Levy DE, Berlin JD et al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. Oncology 2004; 66: 303-309
227. Ridwelski K, Fahlke J, Kuhn R et al. Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma. Eur J Surg Oncol 2006; 32: 297-302
228. Jacobs AD, Otero H, Picozzi Jr VJ et al. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest 2004; 22: 505-514
229. Ulrich-Pur H, Raderer M, Verena Kornek G et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88: 1180-1184
230. Tsavaris N, Kosmas C, Skopetitis H et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 2005; 23: 369-375
231. Reni M, Pasetto L, Aprile G et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94: 785-791
232. Demots A, Peeters M, Polus M et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94: 481-485
233. Oettle H, Arnold D, Esser M et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11: 635-638
234. Burris 3 rd HA, Rivkin S, Reynolds R et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005; 10: 183-190
235. Mitry E, Ducreux M, Ould-Kaci M et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol 2006; 30: 357-363
236. Willett CG, Czito BG, Bendell JC et al. Locally advanced pancreatic cancer. J Clin Oncol 2005; 23: 4538-4544
237. Moertel CG, Childs Jr DS, Reitemeier RJ et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2: 865-867
238. Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation +5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710
239. Klaassen DJ, MacIntyre JM, Catton GE et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3: 373-378
240. Cohen L, Woodruff KH, Hendrickson FR et al. Response of pancreatic cancer to local irradiation with high-energy neutrons. Cancer 1985; 56: 1235-1241
241. Cohen SJ, Dobelbower Jr R, Lipsitz S et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005; 62: 1345-1350
242. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751-755
243. Shinchi H, Takao S, Noma H et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002; 53: 146-150
244. McGinn CJ, Zalupski MM, Shureiqi I et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 19: 4202-4208
245. Kachnic LA, Shaw JE, Manning MA et al. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int J Cancer 2001; 96: 132-139
246. Crane CH, Abbruzzese JL, Evans DB et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002; 52: 1293-1302
247. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783
248. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol 2006; 24: A4008
249. Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J Clin Oncol 2007; 20: 326-331
250. Sa Cunha A, Rault A, Laurent C et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 2005; 201: 359-365
251. Fisher BJ, Perera FE, Kocha W et al. Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1999; 45: 291-295
252. Furuse J, Kinoshita T, Kawashima M et al. Intraoperative and conformai external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer 2003; 97: 1346-1352
253. Brunner TB, Grabenbauer GG, Kastl S et al. Preoperative Chemoradiation in Locally Advanced Pancreatic Carcinoma: A Phase II Study. Onkologie 2000; 23: 436-442
254. Ikeda M, Okada S, Tokuuye K et al. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002; 86: 1551-1554
255. Talamonti MS, Catalano PJ, Vaughn DJ et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000; 18: 3384-3389
256. Brunner TB, Grabenbauer GG, Klein P et al. Phase 1 trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003; 55: 144-153
257. Micke O, Hesselmann S, Bruns F et al. Results and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 2005; 25: 1523-1530
258. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase H Trial. J Clin Oncol 2004; 22: 2610-2616
259. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-3455
260. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3296-3302
261. Beger HG, Link KH, Gansauge F. Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective study. Hepatogastroenterology 1998; 45: 638-643
262. Ghaneh P, Neoptolemos JP. Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy and chemotherapy for pancreatic cancer. Surg Oncol Clin N Am 2004; 13: 567-587, vii-viii
263. Lohr M, Hoffmeyer A, Kroger J et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001; 357: 1591-1592
264. Mercadante S. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. Cancer 1999; 85: 1849-1858
265. Zech DF, Grond S, Lynch J et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63: 65-76
266. Marinangeli F, Ciccozzi A, Leonardis M et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004; 27: 409-416
267. Grahm AL, Andren-Sandberg A. Prospective evaluation of pain in exocrine pancreatic cancer. Digestion 1997; 58: 542-549
268. Caraceni A, Portenoy RK. Pain management in patients with pancreatic carcinoma. Cancer 1996; 78: 639-653
269. Ross GJ, Kessler HB, Clair MR et al. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. Am J Roentgenol 1989; 153: 1309-1311
270. McNicol E, Strassels S, Goudas L et al. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J Clin Oncol 2004; 22: 1975-1992
271. Can DB, Goudas LC, Balk EM et al. Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr 2004; 32: 23-31
272. Payne R, Mathias SD, Pasta DJ et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16: 1588-1593
273. De Conno F, Ripamonti C, Saita L et al. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995; 13: 1004-1008
274. Cherny NI. The management of cancer pain. CA Cancer J Clin 2000; 50: 70-116; quiz 117-120
275. Gilmer-Hill HS, Boggan JE, Smith KA et al. Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer. Surg Neurol 1999; 51: 6-11
276. Staats PS, Hekmat H, Sauter P et al. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study. Pain Med 2001; 2: 28-34
277. Eisenberg E, Can DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995; 80: 290-295
278. Wong GY, Schroeder DR, Carns PE et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. Jama 2004; 291: 1092-1099
279. Stefaniak T, Basinski A, Vingerhoets A et al. A comparison of two invasive techniques in the management of intractable pain due to inoperable pancreatic cancer: neurolytic celiac plexus block and videothqracoscopic splanchnicectomy. Eur J Surg Oncol 2005; 31: 768-773
280. Arenas J, Bodoky G, Bozzetti F et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr 2006; 25: 245-259
281. Arenas J, Zuercher G, Fietkau R et al. DGEM Leitlinie Enterale Ernährung: Onkologie. Akt Ernähr Med 2003; 28: 61-68
282. Bjelakovic G, Nikolova D, Gluud LL et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Jama 2007; 297: 842-857
283. Wigmore SJ, Falconer JS, Plester CE et al. Ibuprofen reduces energy expenditure and acute-phase protein production compated with placebo in pancreatic cancer patients. Br J Cancer 1995; 72: 185-188
284. Gordon JN, Trebble TM, Ellis RD et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540-545
285. Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-573
286. Loprinn CL, Kugler JW, Sloan JA et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17: 3299-3306
287. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev CD 004 200 2006
288. Hausegger KA, Thurnher S, Bodendorfer G et al. Treatment of malignant biliary obstruction with polyurethane-covered Wallstents. Am J Roentgenol 1998; 170: 403-408
289. Isayama H, Komatsu Y, Tsujino T et al. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 2004; 53: 729-734
290. Speer AG, Cotton PB, Russell RC et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62
291. Urbach DR, Bell CM, Swanstrom LL et al. Cohort study of surgical bypass to the gallbladder or bile duct for the palliation of jaundice due to pancreatic cancer. Ann Surg 2003; 237: 86-93
292. DiFronzo LA, Egrari S, O'Connell TX. Choledochoduodenostomy for palliation in unresectable pancreatic cancer. Arch Surg 1998; 133: 820-825
293. Aranha GV, Prinz RA, Greenlee HB. Biliary enteric bypass for benign and malignant disease. Am Surg 1987; 53: 403-406
294. Song HY, Shin JH, Yoon CJ et al. A dual expandable nitinol stent: experience in 102 patients with malignant gastroduodenal strictures. J Vasc Interv Radiol 2004; 15: 1443-1449
295. Kaw M, Singh S, Gagneja H et al. Role of self-expandable metal stents in the palliation of malignant duodenal obstruction. Surg Endosc 2003; 17: 646-650
296. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205
297. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-4107
298. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43: 258-270
299. Schuchter LM, Hensley ML, Meropol NJ et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-2903